CM.TO 1.58V 5.38NRIM 0CSU.TO 12.96NA.TO 2.87META -0.8EXPE 5.16CIGI.TO 3.74
Dimethaid (DMX.TO)

Dimethaid (DMX.TO)

0.00
-0.00 (0.00%)
115 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Dimethaid(DMX.TO)

Sep 15, 2005
New management. Doesn't follow this company actively because it doesn't have much in the way of earnings. In the bottom 10% of his database.
Photo of Robert McWhirterRobert McWhirter
No
Unlock Rating
$0.19

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Jan 25, 2005
Very much news driven. Speculative. Need a very strong stomach.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$0.40

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Nov 27, 2003
Looked like it was going to break out of a 200-day moving average but fell back. Did a special warrant financing in October for sales/marketing of Pennsaid. FDA approval has been pending for a long time. Caution.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.33

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Dimethaid(DMX.TO)

Jul 03, 2003
Has been losing value for some time. Need to have a lot of faith. They are still waiting for a green light from the FDA. The big risk is their inability to move sales.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.74

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Mar 27, 2003
A this point, its a reasonable bet.
Photo of Robert FloydRobert FloydUnlock Rating
$2.09

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Mar 19, 2001
Approaching commercialization.
Photo of Ed HoEd HoUnlock Rating
$7.25

Stock price when the opinion was issued

biotechnologypharmaceutical
WATCH

Dimethaid(DMX.TO)

Jan 02, 2001
Attractive, but wait for partnership deal with Johnson & Johnson
Photo of Steven MisenerSteven MisenerUnlock Rating
$8.10

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Nov 29, 2000
Not a big enough following but should be OK
Photo of Pier DonniniPier DonniniUnlock Rating
$5.60

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Dimethaid(DMX.TO)

Oct 13, 2000
Good techs. Have to convince the Feds its a good way to deliver pain relief
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$5.00

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 1 to 9 of 9 entries
  • «
  • ‹
  • 1
  • ›
  • »
The ultimate 360° Tracker Your financial life in one place, automatically

Dimethaid (DMX.TO) Frequently Asked Questions

What is Dimethaid stock symbol?

Dimethaid is a OTC stock, trading under the symbol DMX.TO (previously DMX-T on Stockchase) on the (). It is usually referred to as or DMX.TO

Is Dimethaid a buy or a sell?

In the last year, there was no coverage of Dimethaid published on Stockchase.

Is Dimethaid a good investment or a top pick?

Dimethaid was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dimethaid.

Why is Dimethaid stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is Dimethaid worth watching?

0 stock analysts on Stockchase covered Dimethaid in the last year. It is a trending stock that is worth watching.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RPRX 0.77$55.63
URA -1.8$44.12
BBD.B.TO 3.33$305.83
X.TO 0.55$50.44
TRI.TO -1.25$114.87

Today's Top Picks

CM.TO 1.58$154.53
V 5.38$325.05
NRIM 0$
CSU.TO 12.96$2975.35
NA.TO 2.87$207.27

Popular Articles

Latest Sell Signals

MDA.TO -1.44$52.57
CPRT 0.45$31.31
TEVA 1.19$34.45
GLXY.TO -1.39$28.26
XNDU.TO 0.55$50.44

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica